166 related articles for article (PubMed ID: 36984543)
1. Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine.
Tanaka T; Okamoto M; Matsuo N; Naitou-Nishida Y; Nouno T; Kojima T; Nishii Y; Uchiyashiki Y; Takeoka H; Nagasaki Y
Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984543
[TBL] [Abstract][Full Text] [Related]
2. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
de Barros CM; Almeida CAF; Pereira B; Costa KCM; Pinheiro FA; Maia LDB; Trindade CM; Garcia RCT; Torres LH; Diwan S; Boralli VB
Pain Physician; 2020 Aug; 23(4S):S351-S366. PubMed ID: 32942793
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease.
Satlin MJ; Goyal P; Magleby R; Maldarelli GA; Pham K; Kondo M; Schenck EJ; Rennert H; Westblade LF; Choi JJ; Safford MM; Gulick RM
PLoS One; 2020; 15(7):e0236778. PubMed ID: 32701969
[TBL] [Abstract][Full Text] [Related]
6. Review on the Clinical Pharmacology of Hydroxychloroquine Sulfate for the Treatment of COVID-19.
Cui C; Tu S; En VSJ; Li X; Yao X; Li H; Liu D
Curr Drug Metab; 2020; 21(6):427-435. PubMed ID: 32520683
[TBL] [Abstract][Full Text] [Related]
7. A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: a preliminary report.
Falcão F; Viegas E; Carmo I; Soares J; Falcao M; Solano M; Cavaco P; Mendes D; Rijo J; Povoa P; Pais Martins A; Carmo E; Mansinho K; Fonseca C; Campos L; Carvalho A; Mirco A; Farinha H; Aldir I; Correia J
Eur J Hosp Pharm; 2021 Sep; 28(5):248-253. PubMed ID: 33452110
[TBL] [Abstract][Full Text] [Related]
8. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19).
Shah S; Das S; Jain A; Misra DP; Negi VS
Int J Rheum Dis; 2020 May; 23(5):613-619. PubMed ID: 32281213
[TBL] [Abstract][Full Text] [Related]
10. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Uzunova K; Filipova E; Pavlova V; Vekov T
Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
12. Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis.
Zang Y; Han X; He M; Shi J; Li Y
Naunyn Schmiedebergs Arch Pharmacol; 2021 Apr; 394(4):775-782. PubMed ID: 32892293
[TBL] [Abstract][Full Text] [Related]
13. Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients That Should Be Ramped Up Immediately as Key to the Pandemic Crisis.
Risch HA
Am J Epidemiol; 2020 Nov; 189(11):1218-1226. PubMed ID: 32458969
[TBL] [Abstract][Full Text] [Related]
14. Long-term application of hydroxychloroquine could not prevent the infection of COVID-19.
Zhu Y; Chen Y; Gong Y; Pan A; Ding H; Fang J; Yu B; Wang B; Ke C; Xu L
J Infect Dev Ctries; 2020 Dec; 14(12):1368-1373. PubMed ID: 33378277
[TBL] [Abstract][Full Text] [Related]
15. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.
Maisonnasse P; Guedj J; Contreras V; Behillil S; Solas C; Marlin R; Naninck T; Pizzorno A; Lemaitre J; Gonçalves A; Kahlaoui N; Terrier O; Fang RHT; Enouf V; Dereuddre-Bosquet N; Brisebarre A; Touret F; Chapon C; Hoen B; Lina B; Calatrava MR; van der Werf S; de Lamballerie X; Le Grand R
Nature; 2020 Sep; 585(7826):584-587. PubMed ID: 32698191
[TBL] [Abstract][Full Text] [Related]
16. Case Report: Hepatotoxicity Associated with the Use of Hydroxychloroquine in a Patient with COVID-19.
Falcão MB; Pamplona de Góes Cavalcanti L; Filgueiras Filho NM; Antunes de Brito CA
Am J Trop Med Hyg; 2020 Jun; 102(6):1214-1216. PubMed ID: 32314698
[TBL] [Abstract][Full Text] [Related]
17. EFFECTS OF HYDROXYCHLOROQUINE PLUS FAVIPIRAVIR TREATMENT ON THE CLINICAL COURSE AND BIOMARKERS IN HOSPITALIZED COVID-19 PATIENTS WITH PNEUMONIA.
Delen LA; Gok A; Kasapoglu US; Cagasar O; Gok Z; Berber N; Derya S; Tetik B
Acta Clin Croat; 2022 Nov; 61(3):403-411. PubMed ID: 37492367
[TBL] [Abstract][Full Text] [Related]
18. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
Kim JW; Kim EJ; Kwon HH; Jung CY; Kim KC; Choe JY; Hong HL
Korean J Intern Med; 2021 Mar; 36(Suppl 1):S253-S263. PubMed ID: 32536150
[TBL] [Abstract][Full Text] [Related]
19. Suspected Hydroxychloroquine-Induced Sinus Bradycardia and QTc Prolongation in a Patient with COVID-19.
Kang Y; Wang H; Chen H; Wang B; Yang Y; Zhao X; Ran Q; Wei J
Int Heart J; 2020 Sep; 61(5):1056-1058. PubMed ID: 32921678
[TBL] [Abstract][Full Text] [Related]
20. Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.
Meriglier E; Rivoisy C; Hessamfar M; Bernard N; Aureau I; Lapoirie J; Contis A; Sacher F; Sacristan B; Lahouati M; Pedeboscq S; Vandenhende MA; Bouchet S; Bonnet F
J Antimicrob Chemother; 2021 Jan; 76(2):482-486. PubMed ID: 33221868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
